L-ascorbic acid (vitamin C) is part of glucose metabolism, which is not accessible to humans since they lack L-gulonolactone oxidase, the last enzyme in the biosynthetic pathway. Therefore, they must obtain it from dietary sources (1). Vitamin C could be found in many fruits such as oranges, grapefruit, strawberries, raspberries, kiwi fruit, and in vegetables such as cabbage, tomatoes, and bell peppers (2). Vitamin C was first isolated by Albert Szent-Gyorgyi in 1928 but the credit for its popularization goes to Linus Pauling. In the 1970s, Pauling implicated the importance of vitamin C in prevention or relief of the simple cold and in the supportive treatment of cancer (3,4). What can be said about vitamin C today, particularly regarding its role in disease prevention and therapy?
The Dietary Reference Intakes (DRI) are the most recent set of dietary recommendations established by the Food and Nutrition Board of the Institute of Medicine, USA, which are based on the evaluation of four categories: Recommended Dietary Allowance (RDA) – the average dietary intake level of a nutrient that prevents a deficiency in 98% of a population, Estimated Average Requirement (EAR) – a nutrient intake value that is estimated to meet the needs of 50% of a population, Adequate Intake (AI) – a value set as a goal for individual intake for nutrients that do not have a RDA, and Tolerable Upper Intake Level (UL) – the highest level of a nutrient that is likely to pose no risk of adverse health effects to 98% of a population. The AI is set instead of an RDA if sufficient scientific evidence is not available to calculate an EAR, such as in infants. The process for setting the RDA depends on being able to set an EAR (5). To provide antioxidant protection, the RDA for adults for vitamin C is set at 75 mg/day for females and 90 mg/day for males. UL for adults is set at 2, 000 mg/day (6). However, many studies have shown that vitamin C intake for optimum reduction of chronic disease risk such as cancer and cardiovascular diseases should be higher than the newest RDA values (7,8). Five servings of fruits and vegetables daily are recomended, because vitamin C as a supplement seems to be less effective in the prevention of diseases and conditions (8).
Vitamin C is an important antioxidant which prevents other compounds from being oxidized. Antioxidative effect of food factors in vivo can be evaluated on the basis of several indices, where vitamin C concentration represents a very sensitive index of oxidative stress (9). It also repairs the tocopheroxyl radical of vitamin E, thereby permitting vitamin E to function again as an antioxidant (10). Vitamin C is a specific electron donor for 8 enzymes involved in collagen, carnitine and noradrenaline biosynthesis, amidation of peptide hormones, and in tyrosine metabolism. It also has non-enzymatic reductive functions in chemical reactions, based on its redox potential and its free-radical intermediate (5). Although vitamin C is a water soluble vitamin which could be easily excretedfrom the body, brain, adrenal cortex, liver, spleen, pancreas and kidney tissues concentrate vitamin C (11). The adrenal gland is among the organs with the highest concentration of vitamin C in the body, where it is required both in catecholamine biosynthesis and adrenal steroidogenesis (12).
When given orally, vitamin C is well absorbed at lower doses, but absorption decreases as the dose increases. In the blood, vitamin C is not protein bound, so it is filtered and reabsorbed by kidneys. It probably passes unchanged through glomeruli and undergoes concentration-dependent active tubular reabsorption by a vitamin C transport protein. When the transport protein reaches saturation, remaining vitamin C is not transported, and it is excreted in urine. Vitamin C begins to appear in urine at doses above 100 mg/day (11), while complete plasmasaturation occurs at 1,000 mg/day (8).
Vitamin C is transported across cellular membranes most likely by two distinct mechanisms. Ascorbic acid is easily oxidized to the dehydroascorbic acid (DHA) which is rapidly taken up by cells and reduced to ascorbic acid, using glutathione for reduction (13). Because ascorbate oxidized extracellularly is recycled intracellularly, the process is called “ascorbate recycling”. The specific glucose transporter isoforms, GLUT1 and GLUT3, mediate DHA transport because of its similarity to the molecule of glucose (14). GLUT1 is widely tissue distributed, while GLUT3 is primarily expressed in brain, placenta, testis, and platelets. On the other hand, ascorbic acid is transported into the cell by sodium-dependent vitamin C transporters SVCT1 and SVCT2, one or both of which are found in most tissues (15). Mutant mice SVCT2 have severely reduced tissue levels of ascorbic acid and die soon after birth. The influence of the SVCT2 deficiency on tissue catecholamines is most prominent in the adrenals, where both epinephrine and norepinephrine are decreased over 50% (16). It stillremains unclear which pathways, either SVCT1 and SVCT2 or GLUT1 and GLUT3, dominate in vivo.
Vitamin C has various forms, depending on pH media and its oxidation state (Figure 1). In physiological conditions, 99.95% of vitamin C is present as AscH–, ascorbate monoanion or just “ascorbate” (17).
Figure 1. The equilibrium and redox species in the ascorbic acid-dehydroascorbic acid system. AscH2 (ascorbic acid), AscH-(ascorbate monoanion), Asc2- (ascorbate dianion), AscH˙ (ascorbyl radical), Asc·-(ascorbate radical), DHA (dehydroascorbate), DHAA(1) and DHAA(2) (dehydroascorbate hydrolyzed forms) (17).
Interacting with reactive radicals or lipid hydroperoxides, ascorbate releases one electron and a much less reactive ascorbyl radicalis formed. Recently it has been shown that ascorbate can mediate the conversion of hydroperoxy octadecadienoic acids (HPODE) into genotoxic 4-hydroxy-2-nonenal (HNE). However, ascorbate also forms a conjugate with HNE by Michael addition, a two-electron reaction in which ascorbic acid plays the role of a nucleophile. Therefore, vitamin C acts as an electron donor to HPODE, causing HNE formation, and subsequently acts as a detoxifying agent against HNE by functioning as a Michael donor (Figure 2) (18).
Figure 2. Vitamin C as a one-electron donor and a Michael donor. Vitamin C may function as a one-electron donor to HPODE, thereby inducing formation of the alkoxy radical. The alkoxy radical then undergoes α,β-carbon-carbon bond cleavage, generating HNE as well as other LPO products. Vitamin C may also function as a Michael donor and react with HNE and other LPO products, giving a variety of ascorbyl-LPO product conjugates(18).
On the other hand, ascorbyl radicalundergoes a disproportional reaction, regenerating some ascorbate and producing DHA. DHA is unstable and degradates rapidly in a complex way, eventually producing oxalic and L-threonic acid (Figure 3) (19).
Figure 3. The degradation of ascorbate.
Antioxidant micronutrients, as well as antioxidant enzymes, are the body’s defense systems against free radicals and reactive molecules. The generation of highly reactive oxygen metabolites is a feature of normal cellular metabolism. It is a part of the body’s natural immune system, mitochondrial respiratory chain, arachidonic acid metabolism, ovulation and fertilization. Although free-radical species are continuously produced in the human body, their production can multiply during pathological circumstances (20). Halliwell suggested that the administration of antioxidants can have protective effects or worsen damage, depending on where one is in the sequence of events (21). Administration of a powerful antioxidant after oxidative damage has started could promote damage, and the more powerful the antioxidant is as a reducing agent, the more problems it might cause.
Therefore, it is not a surprise that data related to macromolecular oxidation and high vitamin C intake are inconsistent. They suggest a protective role in DNA oxidation (22,23), but also a pro-oxidant, as well as an antioxidant effect in healthy humans (24). Other data show no effect of high vitamin C intake on either DNA damage or protection against hydrogen peroxide-induced toxicity (25), or efficiency in protecting against chromosome damage (26). On the other hand, a deficiency of vitamin C and some other vitamins and minerals damage DNA by causing single- and double-strand breaks and oxidative lesions (27). Ability of vitamin C to damage DNA, lipids and proteins in vitro is attributed to the formation of reactive oxygen species in the presence of traces of transition metal ions, such as superoxide anion radical and hydrogen peroxide (28):
AscH– + O2 → AscH˙– + O2˙–
AscH– + O2˙– → AscH˙– + H2O2
or even hydroxyl radical (OH·) (29):
Fe(III) + AscH– →Fe(II) + Asc·-
Fe(II) + H2O2 → Fe(III) + OH· + OH-
Hydroxyl radical, one of the most potent free radicals known, can initiate lipid peroxidation, cause DNA strand breaks and oxidize virtually any organic molecule (30,31). Treatment of rats with vitamin C, after chemically induced OH· formation, suppressesthe generation of the radical (32). In healthy volunteers, iron and vitamin C co-supplementation enhanceoxidative DNA damage which is normalized afterwards, perhaps due to adaptations in the cell, such as increase in repair enzyme levels or better sequestration of iron into ferritin (33). However, vitamin C does not further increase the oxidative stress induced by high dietary iron (34). It is noteworthy that iron and copper ions are mainly sequestered in forms unable to catalyse free radical formation. Therefore, their oxidative effect is very limited. Although it still could happen, it is probably masked by the dominant antioxidative effect of vitamin C (20). Indeed, in human plasma taken in vitro, vitamin C acts in the presence of redox-active iron or copper and hydrogen peroxide as an antioxidant which prevents lipid peroxidation and does not promote protein oxidation (35).
Cigarette smokers are known to be exposed to a large number of oxidants (36). Mean levels of vitamin C in the plasma of smokers are twice lower when compared to nonsmokers (37), which increasesthe requirement for vitamin C in smokers. Pretreatment with either vitamin C or vitamin E completely inhibits the DNA damage induced by extracts from cigarette smoke (38). Furthermore, cigarette smoking is associated with endothelial dysfunction including impaired endothelium-dependent flow-mediated dilation (39). The combined usual dosage of vitaminC and E supplements improve the endothelial function in chronic smokers. Also, vitamin C restores impaired coronary flow velocity reserve against oxidative stress in smokers (40).
The amounts of vitamin C which safely protect from scurvy may still be too low to provide an efficient rate for other, most likely antioxidant reactions in infected people (41). RDA for vitamin C has health benefit in humans, but higher doses may have the potential therapeutic effects. Clinical studies provide evidence that wound healing in subjects not deficient in vitamin C also can be significantly accelerated with daily dosages of 0.5 to 3 g (42). In cultured human keratinocytes vitamin C acts as a modulator of proliferation and differentiation, directly affecting the keratinocyte or indirectly through effects on fibroblasts (43). Vitamin C modulates the growth and maturation of chondrocytes, and accelerates bone fracture healing (44,45).
Vitamin C participation in immunological defense system has been frequently reported. Phagocytes produce free radicals as
a part of the body’s defense against infection, and adequate amounts of a neutralizing antioxidant are required to prevent damage to the immune cells themselves (46). Vitamin C stimulates the phagocytic response of murine peritoneal macrophages (47), as well as the proliferative response of B and T lymphocytes and interleukin-2 and interleukin-6 production in pigs with hereditary deficiency in vitamin C synthesis (48). In humans, combined supplementation with vitamins C and E seems to be even more immunopotentiating than supplementation with either vitamin alone (49).
Decreased blood levels of vitamin C can be found in various diseases. They are associated with, e.g., diabetes mellitus (50), acute pancreatitis (51), asthma (52) or an unstable coronary syndrome (53). Dose concentration studies of vitamin C in healthy people show a sigmoidal relationship between oral dose and plasma and tissue vitamin C concentrations. Therefore, optimal dosing is critical to intervention studies using vitamin C (54).
The role of vitamin C supplement in the prevention and treatment of colds remains controversial despite many controlled trials. Studies have shown that high doses of vitamin C taken shortly after onset of a cold did not reduce the duration or severity of cold symptoms in healthy adults (55), but also highly decreased flu and cold symptoms (56). Comparative analysis of thirty trials has shown a modest benefit in reducing duration of cold symptoms from high vitamin C intake (57). The preventive effects of the supplementation seemto be limited mainly to subjects with low dietary vitamin C intake, but therapeutic effects may occur in wider population groups (58). High dose prophylaxis could be notably justified in persons exposed to brief periods of severe physical exercise and/or cold environments. When subjects were under heavy exertion during the trial, like military recruits, the vitamin C protective effect in respiratory infections was highly emphasized (59). Recently, a randomized, controlled 5-year trial suggested that vitamin C supplementation significantly reduces the frequency of the common cold but had no apparent effect on itsduration or severity (60).
Most likely different study conditions provide explanation why so many trials give such contradictory outcomes. Cold symptoms vary diurnally (61), and susceptibility to colds is also increased in smokers, while moderate alcohol consumption is associated with decreased risk in nonsmokers (62). Psychological stress is also associated in a dose-response manner with an increased risk of acute infectious respiratory illness generally (63). It seems that vitamin C produces a greater benefit in cold duration for children than for adults. The dose may also affect the magnitude of the benefit, and there ison average greater benefit from 2 g/day compared to 1 g/day of the vitamin (64). The beneficial effect of vitamin C during a cold probably stemsfrom its antioxidant properties. In an infection, phagocytic leukocytes become activated producing oxidizing compounds that are released from the cells. By reacting with these oxidants, vitamin C may decrease the inflammatory effects that they produce (65).
Asthma is primarily an inflammatory diseaseof the airways. Vitamin C plays an essential role in defending against oxidant attack in the airways. Its deficiency in the sputum of asthmatics may be either an underlying factor in the pathophysiology of asthma or a response to asthmatic airway inflammation (65). In exercise-induced asthma, the use of vitamin C supplementation at a dosage of 1 to 2 g per day hasa protective effect in some patients (66). Although studies of vitamin C supplementation suggest a short-term protective effect on airway responsiveness and pulmonary function, a protective effect of vitamin C on the developmentof chronic asthma remains to be established.
Several studies showed a beneficial association between fruit and vegetable intake and lung function (67,68). The forced expiratory volume in 1 second in subjects with the intake of fruits once per week or more was about 80–100 mL higher than in subjects with the intake less than once per week. A 100 mg increase in vitamin C intake per day is also associated with an approximately 10–50 mL increase in forced expiratory volume in 1 second (69).
Dietary intake of 100 mg/day of vitamin C is associated with reduced incidence of, or mortality from heart diseases, stroke and cancer (7). In elderly people, vitamin C seems to be related to subsequent risk of death from stroke, but not from coronary heart disease (70). Stroke, coronary heart disease, and peripheral vascular diseasehave many risk factors in common, yet somefactors are more important for one cardiovascular disease than another. A high plasma fibrinogenconcentration may be equally importantin all these conditions (71). Increased concentrations of fibrinogen provide a biologically persuasive mechanism by which acute or chronic infection could increase cardiovascular risk. Vitamin C in 2 g/day dose increases fibrinolytic activity and decreases the platelet adhesive index and serum cholesterol (72). Frequent intake of fruit and vegetables, food rich in vitamin C, also increases activity of the fibrinolytic system by lowering plasminogen activator inhibitor activity (73). Seasonal variations in both respiratory infection and cardiovascular disease are attributed to decrease in vitamin C and increase in fibrinogen serum levels during the winter(74).
Total cholesterol, low-density-lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) are among the major risk factors for cardiovascular disease (75). Several studies reported negative correlation between serum vitamin C and total cholesterol (76,77), and positive correlations between serum vitamin C and HDL (78), at least among women (79), but not all studies (80). It seems that vitamin C is involved in cholesterol metabolism in several ways. It reduces 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterolsynthesis (81,82). It also activates cholesterol-7a-hydroxylase in rats, and the catabolism of cholesterol to bile acids (83).
Intake of antioxidant nutrients may protect against coronary heart disease, because oxidation of lipoproteins is hypothesized to promote atherosclerosis (84,85). It is presumed that oxidized LDL has an atherogenic potential due to lipid peroxidation (86). Ascorbate completely protects plasma lipids against detectable peroxidative damage induced by aqueous peroxyl radicals and it is the only plasma antioxidant that can do so (87). Vitamin C protects against neutrophil-mediated LDL oxidation, most likely due to the scavenging of extracellular oxidants. It also prevents pro-oxidant effects of urate in LDL oxidation (88). Further, vitamin C could help prevent atherosclerosis by strengthening the artery walls through its participation in the synthesis of collagen, and by preventing the undesirable adhesion of white blood cells to damaged arteries (89).
As a powerful antioxidant, vitamin C reverses endothelial dysfunction due to increased oxidative stress, preventing hyperoxic vasoconstriction (90). It also improves lipid-induced impairment of endothelium-dependent vasodilation (91). Experimental studies of essential hypertension suggest that increased production of reactive oxygen species may play a role in the etiology (92). They also show that higher serum levels of vitamin Care consistently and significantly related to lower systolicand diastolic blood pressure among middle-aged or elderly populations (93,94). It has been suggested that 500 mg of vitamin C daily is useful for blood pressure control in patients with hypertension (95). However, in a double-blind, randomized, placebo-controlledcrossover study clinic blood pressure was notreduced after supplementation with 500 mg vitamin C per dayfor 3 months, although daytime levels of ambulatory systolicblood pressure wereslightly reduced (96).
No conclusive evidence is available on the protective effect of vitamin C supplementation on cardiovascular risk, although they implicate a beneficial effect. On the other hand, a diet rich in fruits and vegetables is highly protective against atherosclerosis and coronary heart disease (97,98).
Oxidative stress may play a pronounced role in neurodegenerative diseases. Alzheimer’s disease is the most common cause of dementia associated with aging. It seems that supplementation with antioxidants may delay the development of Alzheimer’s disease. Combination of vitamin E and vitamin C supplements is associated with reduced prevalence and incidence of Alzheimer’s disease (99). Vitamin C and melatonin have beneficial effect on lipid peroxide levels and the activity of antioxidant enzymes in a model of Alzheimer’s disease, suggesting their possible use in the treatment of neurodegenerative diseases (100). Vitamin C also provides protection against scopolamine- and diazepam-induced impairment of memory in mice. The underlying mechanism of memory-restorative action could also be attributed to its antioxidant property (101).
Antioxidant and general immunostimulant properties of vitamin C could be beneficial to cancer patients, including tumor regression, and the inhibition of tumor growth. Epidemiological studies show that vitamin C has a protective effect against, in particular, non-hormone-dependent malignancies (102). Experimental in vivo and in vitro studies, however, yielded more controversial results, suggesting that the effects of vitamin C are dose- and perhaps time-dependent with different effects, depending on the species and organ studied or cancer cell type (103).
In the 1970s, Pauling and Cameron used vitamin C in gram quantities in the treatment of patients with advanced stage of cancer. Their results showed improvement of general condition of tested subjects. Most of the patients subjectively felt much better, with reduced pain seizures, and prolonged lifetime (4). Although an experiment performed in Japan yielded similar results (104), a report from the eminent Mayo Clinic showed no effect of vitamin C in cancer treatment (105). However, in the following years researchers revealed a possible role of vitamin C in the cancer prevention. Consumption of foods rich in vitamin C is associated not only with decreased risk of cardiovascular disease, but also of many types of cancer and possibly neurodegenerative diseases. However, the extent to which vitamin C contributes to these effects is still uncertain (106). Reduction in cancer risk is more likely to be achieved through dietary modification, rather than through vitamin supplementation (107). Diets with 200 mg or more of vitamin C per day, obtained from five servings of fruits and vegetables, are associated with lower cancer risk, especially for cancers of the oral cavity, esophagus, stomach, colon and lung. Although several different factors in fruits and vegetables probably act jointly, the epidemiological and biochemical evidence indicates an important role for vitamin C (108).
Supplementation with antioxidants is associated with a decrease in the percentage of cells with chromosome aberrations, andwith beneficial effect in smokers (109). Vitamin C at high concentrations seems to be toxic to cancer cells in vitro (110,111). These concentrations can be achieved in plasma only by intravenous administration. Therefore, negative cancer protective results might originate from the use of oral rather than intravenous vitamin C (11). Following the administration of 1.25 g intravenously, a peak plasma level of 1,000 µmol/L could be reached, although 100 µmol/L could not be exceeded by oral dosing due to limiting absorptive mechanism (112). Most recent data show that, depending on the dose and infusion rate, peak plasma concentrations obtained intravenously can reach 14,000 μmol/L, and concentrations above 2,000 μmol/L may persist for several hours (113). Vitamin C, in concentrations which can be achieved only by intravenous administration, may act as a pro-drug for the formation of hydrogen peroxide, causing death of several studied cancer cell types but no normal cells (114). Diets high in fruit and vegetables, and hence high in vitamin C, have been found to be associated with lower risk for cancers of the oral cavity, esophagus, stomach, colon, and lung (115). Formation of nitrosamines, which is associated with gastric cancer, can be decreased by administration of vitamin C (116). Vitamin C also induces the apoptosis of various cancer cell types by acting as a pro-oxidant and increasing intracellular reactive oxygen species levels (117,118). On the other hand, at lower concentrations vitamin C displays antioxidant property, preventing spontaneous and stress- or antitumor agent-induced apoptosis (116). Furthermore, vitamin C can induce transient cell cycle arrest. Vitamin C inhibits DNA synthesis in HeLa (human cervix adenocarcinoma) cells, delaying the entry of p53-deficient synchronized HeLa and T98G (human glioblastoma multiform) cancer cells into mitosis (119). Fatty acid esters of ascorbic acid have attracted considerable interest as anticancer compounds due to their lipophilic nature which enables their crossing through cell membranes and blood-brain barrier. Ascorbyl stearate inhibits cell proliferation by interfering with cell cycle and induces apoptosis by modulation of insulin-like growth factor 1-receptor expression in T98G and pancreatic cancer cells (120,121).
Current evidence suggests that vitamin C alone may not be effective enough in the treatment of most active cancers. However, vitamin C improves the quality of life and extends longevity in cancer patients, which are the reasons why it should be considered as a supplement in cancer therapy (122).
Diabetes mellitus is another disease associated with an increased production of reactive oxygen species and a reduction in antioxidant defenses. This leads to oxidative stress, which is partially responsible for diabetic complications (123). Vitamin C status depends on the interactions of dietary intake, plasma insulin concentrations and glycemia. Insulin promotes the active cellular uptake of vitamin C, whereas hyperglycemia inhibits renal vitamin C reabsorption. Oxidative stress is a common pathogenetic factor of diabetic nephropathy. Since DHA and glucose compete for glucose transporters, hyperglycemia discharges vitamin C from tubular epithelial cells, resulting in decreased antioxidant capacity (124). Hyperglycemia and oxidative stress are responsible for endothelial dysfunction in diabetic patients. Intraarterial infusion of vitamin C improves endothelium-dependent vasodilation in patients with either type 1 or type 2 diabetes (125,126). On the other hand, oral high dose of vitamin C could not replenish vitamin C levels and improve endothelial dysfunction (127). Low intracellular levels of vitamin C in individuals with both hyperglycemia and low plasma levels of vitamin C may be responsible for the increasedlevels of DNA damage in such patients. Thus, poorly controlled diabetic subjects might benefit from increased dietary vitamin C (128).
Vitamin C, found in high concentrations in the lens, may be of importance for the prevention of cataract in older population (129). Although oxidative damage in the lens can be prevented by vitamin C, a pro-oxidant effect of vitamin C through hydrogen peroxide generation has alsobeen suggested. On the other hand, vitamin C could play a role in protein glycation, which is observed in cataract formation (130,131). In vitro irradiation of aged human lenses with UVA in the presence of vitamin C causes extensive destruction of their chromophores in the UV and visible region, which could be related to glycation products of proteins in lens fiber cells (132). Although mostepidemiological evidence suggests that it is prudent to consume diets high in vitamin C, vitamin E and carotenoids as insurance against the development of cataract (133), it is not yet possible to conclude that antioxidant nutrients have a role in prevention of cataract.
Vitamin C supplements are generally well tolerated. However, high doses may cause stomach irritation, nausea, vomiting, drowsiness, headaches or rash2. Adverse reactions are rarely, if ever, seen when the nutrient is consumed according to established guidelines. It should be emphasized that UL values, which are designed to protect the most sensitive individuals in the general population, are not intended to apply to the most sensitive persons in sensitive subpopulations (134). There should be a caution with a highsupplement intake generally, as well as vitamin C, in these individuals. Thus, single 6 g dose of vitamin C induces hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency (135).
Vitamin C has been recognized as the enhancer of the intestinal absorption of dietary inorganic iron, either by reducing it or preventing its chelation by phytates or other food ligands (136). However, it seems unlikely that vitamin C induces iron overabsorption in healthy people (137). Although there has been some concern that people suffering from hemochromatosis (a tendency to iron overload) may be sensitive to high dosages of vitamin C, it seems that vitamin C is entirely safe, even in daily quantities of 10 g or more (138,139).
The contribution of ascorbate to oxalate kidney stone formation is controversial. Since oxalate is a vitamin C catabolitic product, certain concern has beenraised for oxalate excretion. Since gastrointestinal absorption as well as renal tubular reabsorption of vitamin C are saturable processes and the metabolic transformation to oxalate is limited as well, vitamin C should not increase the risk of calcium oxalate kidney stones (140). Thus, an association between high vitamin C intake and increased urinary oxalate excretion(141) or the risk of stone formation (142) has not been found in healthy adults. However, some findings suggested safe vitamin C intake to be less than 1 g daily (8). In some individuals, metabolic conversion of ascorbate to oxalate can cause relative hyperoxaluria and crystalluria, the latter manifesting as hematuria (143). Increased urinary oxalate excretion by intravenous vitamin C administration predisposes susceptible individuals to nephrolithiasis (144). The ingestion of high vitamin C doses should be contraindicated in cases of renal insufficiency, hemodialysed patients, and oxalate stoneformers (145).
Data concerning the effect of vitamin C on urate excretion are also contradictory. Several studies have found elevated urate excretion after prolonged high dietary vitamin C intake (5,146), but not all (147,148). The conflicting findings may be due to lack of steady-state for vitamin C, differences in plasma concentrations, or duration of vitamin C administration. However, in all reports hyperuricosuria was absent at vitamin C doses less than 1 g/day.
High dietary vitamin C intake can also affect certain laboratory diagnostic tests, producing false positive readings in urine glucose tests, protein levels in cerebrospinal fluid and urine, as well as false negative readings in urine bilirubin tests. It also decreases serum bilirubin, cholesterol, creatinine, and triglyceridevalues (145).
Some harmful effects have been mistakenly attributed to vitamin C, including hypoglycemia, rebound scurvy, infertility, mutagenesis, and destruction of vitamin B12 (8).
Drug interactions with vitamin C high doses seem to be very rare. There are some conflicting reports about the effect of vitamin C on decreased anticoagulation response to warfarin or dicoumarol (149). High doses of vitamin C also can reduce steady-state plasma concentrations of indinavir, a protease inhibitor indicated for treatment of the human immunodeficiency virus type 1 (150). On the other hand, vitamin C can improve levodopa absorption in elderly patients with Parkinson disease and with poor levodopa bioavailability (151). High vitamin C intake could also interfere with other drugs, which remains to be established. In addition, diarrhea caused by large oral vitamin C doses can reduce the intestinal absorption generally.
Vitamin C achieves positive results in numerous health conditions, acting primarily as anantioxidant (Table 1). On the basis of current evidence, it is justified to promote diets rich in vitamin C for the prevention against cardiovascular disease and cancer. Vitamin C supplements are beneficial in wound healing, reducing the incidence of common cold primarily in heavily physically stressed persons. It is also effective in preventing plasma lipid peroxidation, and decreasing serum fibrinogen and cholesterol values as risk factors for cardiovascular disease.Howeverer, some positive effects could be achieved only by intraarterial or intravenous administration of vitamin C, such as in patients with diabetes melitus and some types of cancer.The evidence from observational studies also suggests a role of vitamin C in asthma and obstructive pulmonary disease, although causality of the association has not been confirmed. Despite contradictory reports, the consensus from extensive literature is that adverse health effects are not induced in healthy persons by ingesting high doses of vitamin C. However, there should be a caution in persons with some specific metabolic disorders.
Table 1. The effect of vitamin C in various health conditions
The evidence in this review provides a substantial basis for further research, both clinical and experimental trials. Oral supplementation of vitamin C cannot yield plasma concentrations as high as parenteral administration. Therefore, further research into vitamin C, particularly as a treatment agent for cancer, as well as clinical study of safety and efficacy of intravenous administration of vitamin C, should be performed to confirm over three decades old Linus Pauling’s idea.
1. Smirnoff N. L-ascorbicacid biosynthesis. Vitam Horm 2001;61:241-66.
2. Kaegi E. Unconventional therapies for cancer: Vitamins A, C and E. Can Med Assoc J 1998;158(11):1483-8.
3. Pauling L. Ascorbic acid and the common cold. Am J Clin Nutr 1971;24(11):1294-9.
4. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 1978;75(9):4538-42.
5. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996; 93(8):3704-9.
6. Food and Nutrition Board, Institute of Medicine, US National Academy of Science. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academy Press, Washington; 2000, pp 95-185.
7. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 1999;69(6):1086-107.
8. Levine M, Rumsey SC, Daruwala RC, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. JAMA 1999;281(15):1415-23.
9. Kojo S. Vitamin C: basic metabolism and its function as an index of oxidative stress. Curr Med Chem 2004;11(8):1041-64.
10. Buettner GR. The pecking order of free radicals, antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch Biochem Biophys 1993;300(2):535-43.
11. Padayatty SJ, Levine M. New insights into the physiology and pharmacology of vitamin C. Canad Med Assoc J 2001;164(3):353-5.
12. Patak P, Willenberg HS, Bornstein SR. Vitamin C is an important cofactor for both adrenal cortex and adrenal medulla. Endocr Res 2004;30(4):871-5.
13. Rumsey SC, Levine M. Absorption, transport, and disposition of ascorbic acid in humans. J Nutr Biochem 1998;9:116-30.
14. Rumsey SC, Kwon O, Xu GW, Burant CF, Simpson I, Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem 1997;272:18982-9.
15. Tsukaguchi H, Tokui T, Mackenzie B, Berger UV, Chen XZ, Wang Y, et al. A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature 1999;399:70-5.
16. Bornstein SR, Yoshida-Hiroi M, Sotiriou S, Levine M, Hartwig HG, Nussbaum RL, et al. Impaired adrenal catecholamine system function in mice with deficiency of the ascorbic acid transporter (SVCT2). FASEB J 2003;17(13):1928-30.
17. Bors W, Buettner GR. The vitamin C radical and its reactions. In: Vitamin C in Health and Disease. Packer L, Fuchs J, eds. New York: Marcel Dekker; 1997; 75-94.
18. Sowell J, Frei B, Stevens JF. Vitamin C conjugates of genotoxic lipid peroxidation products: structural characterization and detection in human plasma. Proc Natl Acad Sci U S A 2004;101(52):17964-9.
19. Halliwell B, Gutteridge JMC. Ascorbic acid. In: Free radicals in biology and medicine. 3rd ed. Oxford Press, Oxford; 1999;200-8.
20. Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, et al. Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 2005;280(6):4254-63.
21. Halliwell B. The antioxidant paradox. Lancet 2000;355(9210):1179-80.
22. Bijur GN, Briggs B, Hitchcock CL, Williams MV. Ascorbic acid-dehydroascorbate induces cell cycle arrest at G2/M DNA damage checkpoint during oxidative stress. Environ Mol Mutagen 1999;33(2):144-52.
23. Lenton KJ, Therriault H, Fulop T, Payette H, Wagner JR. Glutathione and ascorbate are negatively correlated with oxidative DNA damage in human lymphocytes. Carcinogenesis 1999;20(4):607-13.
24. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J. Vitamin C exhibits pro-oxidant properties. Nature 1998;392:559-66.
25. Crott JW, Fenech M. Effect of vitamin C supplementation on chromosome damage, apoptosis, necrosis ex vivo. Carcinogenesis 1999;20(6):1035-41.
26. Antunes LM, Takahashi C. Effects of high doses of vitamins C and E against doxorubicin-induced chromosomal damage in Wistar rat bone marrow cells. Mutat Res 1998;419(1-3):137-43.
27. Ames BN. DNAdamage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res 2001;475(1-2):7-20.
28. Scarpa M, Stevanato R, Vigilino P, Rigo A. Superoxide ion as active intermediate in the auto oxidation of ascorbate by molecular oxygen. Effect of superoxide dismutase. J Biol Chem 1983;258(11):6695-7.
29. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85.
30. Burkitt MJ, Duncan J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch Biochem Biophys 2000;381(2):253-63.
31. McCord M. The evolution of free radicals and oxidative stress. Am J Med 2000;108(8):652-9.
32. Shankaran M, Yamamoto BK, Gudelsky GA. Ascorbicacid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxylradical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 2001;40(1):55-64.
33. Rehman A, Collis CS, Yang M, Kelly M, Diplock A T, Halliwell B, Rice-Evans E. The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers. Biochem Biophys Res Commun 1998;246:293-8.
34. Premkumar K, Bowlus CL. Ascorbic acid does not increase the oxidative stress induced by dietary iron in C3H mice. J Nutr 2004;134(2):435-8.
35. Suh J, Zhu BZ, Frei B. Ascorbate does not act as a pro-oxidant towards lipids and proteins in human plasma exposed to redox-active transition metal ions and hydrogen peroxide. Free Radic Biol Med 2003;34(10):1306-14.
36. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985;64:111-26.
37. Gackowski D, Kowalewski J, Siomek A, Olinski R. Oxidative DNA damage and antioxidant vitamin level: comparison among lung cancer patients, healthy smokers and nonsmokers. Int J Cancer 2005;114(1):153-6.
38. Chen HW, Chien ML, Chaung YH, Lii CK, Wang TS. Extracts from cigarette smoke induce DNA damage and cell adhesion molecule expression through different pathways. Chem Biol Interact 2004;150(3):233-41.
39. Takase B, Etsuda H, Matsushima Y, Ayaori M, Kusano H, Hamabe A, et al. Effect of chronic oral supplementation with vitamins on the endothelial function in chronic smokers. Angiology 2004;55(6):653-60.
40. Teramoto K, Daimon M, Hasegawa R, Toyoda T, Sekine T, Kawata T, Yoshida K, Komuro I. Acute effect of oral vitamin C on coronary circulation in young healthy smokers. Am Heart J 2004;148(2):300-5.
41. Hemila H. Vitamin C and the common cold. Brit J Nutr 1992;67:3-16.
42. Ringsdorf WM Jr, Cheraskin E. Vitamin C and human wound healing. Oral Surg Oral Med Oral Pathol 1982;53(3):231-6.
43. Wha Kim S, Lee IW, Cho HJ, Cho KH, Han Kim K, Chung JH, et al. Fibroblasts and ascorbate regulate epidermalization in reconstructed human epidermis. J Dermatol Sci 2002;30(3):215-23.
44. Freyria AM, Ronziere MC, Roche S, Rousseau CF and Herbage D. Regulation of growth, protein synthesis, and maturation of fetal bovine epiphyseal chondrocytes grown in high-density culture in the presence of ascorbic acid, retinoic acid, and dihydrocytochalasin. B J Cell Biochem 1999;76:84–98.
45. Sarisozen B, Durak K, Dincer G, Bilgen OF. The effects of vitamins E and C on fracture healing in rats. J Int Med Res 2002;30(3):309-13.
46. Hughes DA. Effects of dietary antioxidants on the immune function of middle-aged adults. Proc Nutr Soc 1999;58:79-84.
47. Del Rio M, Ruedas G, Medina S, Victor VM, De La Fuente M. Improvement by several antioxidants of macrophage function in vitro. Life Sci 1998;63:871-81.
48. Schwager J, Schuize J. Modulation of interleukin production by ascorbic acid. Vet Immunol Immunopathol 1998;64:45-57.
49. Jeng KC, Yang CS, Siu WY, Tsai YS, Liao WJ, Kuo JS. Supplementation with vitamins C and E enhances cytokine production by peripheral blood mononuclear cells in healthy adults. Am J Clin Nutr 1996;64:960-5.
50. Will JC, Byers T. Does diabetes mellitus increase the requirement for vitamin C? Nutr Rev 1996;54(7):193-202.
51. Bonham MJ, Abu-Zidan FM, Simovic MO, Sluis KB, Wilkinson A, Winterbourn CC, et al. Early ascorbic acid depletion is related to the severity of acute pancreatitis. Brit J Surg 1999;86(10):1296-1301.
52. Vural H, Uzun K. Serum and red blood cell antioxidant status in patients with bronchial asthma. Can Respir J 2000;7(6):476-80.
53. Vita JA, Keaney JF Jr, Raby KE, Morrow JD, Freedman JE, Lynch S, et al. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome. J Am Coll Cardiol 1998;31(5):980-6.
54. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 2003;22(1):18-35.
55. Audera C, Patulny RV, Sander BH, Douglas RM. Mega-dose vitamin C in treatment of the common cold: a randomised controlled trial. Med J Aust 2001;175(7):359-62.
56. Gorton HC, Jarvis K. The effectiveness of vitamin C in preventing and relieving the symptoms of virus-induced respiratory infections. J Manipulative Physiol Ther 1999;22(8):530-33.
57. Douglas RM, Chalker EB, Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev 2004;(2):CD000980.
58. Hemila H, Douglas RM. Vitamin C and acute respiratory infections. Int J Tuberc Lung Dis 1999;3(9):756-61.
59. Hemila H. Vitamin C supplementation and respiratory infections: a systematic review. Mil Med 2004;169(11):920-5.
60. Sasazuki S, Sasaki S, Tsubono Y, Okubo S, Hayashi M, Tsugane S. Effect of vitamin C on common cold: randomized controlled trial. Eur J Clin Nutr 2006;60(1):9-17.
61. Smith A, Tyrrell D, Coyle K, Higgins P, Willman J.Diurnal variation in the symptoms of colds and influenza. Chronobiol Int 1988;5(4):411-6.
62. Cohen HA, Neuman I, Nahum H. Blocking effect of vitamin C in exercise-induced asthma. Arch Pediatr Adolesc Med 1997;151(4):367-70.
63. Cohen S, Tyrrell Da, Smith AP. Psychological stress and susceptibility to the common cold.N Engl J Med 1991;325(9): 606-12.
64. Hemila H. Vitamin C supplementation and common cold symptoms: factors affecting the magnitude of the benefit. Med Hypotheses 1999;52(2):171-8.
65. Kongerud J, Crissman K, Hatch G, Alexis N.Ascorbic acid is decreased in induced sputum of mild asthmatics. Inhal Toxicol 2003;15(2):101-9.
66. Cohen HA, Neuman I, Nahum H. Blocking effect of vitamin C in exercise-induced asthma. Arch Pediatr Adolesc Med 1997;151(4):367-70.
67. Butland BK, Fehily AM, Elwood PC. Diet, lung function, and lung function decline in a cohort of 2512 middle aged men. Thorax 2000;55:102-8.
68. Hu G, Zhang X, Chen J, Peto R, Campbell TC, Cassano PA. Dietary vitamin C intake and lung function in rural China. Am J Epidemiol 1998;148:594-9.
69. Smit HA, Grievink L, Tabak C. Dietary influences on chronic obstructive lung disease and asthma: a review of the epidemiological evidence. Proc Nutr Soc 1999;58(2):309-19.
70. Gale CR, Martyn CN, Winter PD, Cooper C. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ 1995;310:1563-6.
71. Bulpitt CJ. Vitamin C and vascular disease. BMJ 1995;310:1548-9.
72. Bordia AK.The effect of vitamin C on blood lipids, fibrinolytic activity, platelet adhesiveness in patients with coronary artery disease. Atherosclerosis 1980;35(2):181-7.
73. Nilsson TK, Sundell IB, Hellsten G, Hallmans G. Reduced plasminogen activator inhibitor activity in high consumers of fruits, vegetables and root vegetables. J Intern Med 1990;227(4):267-71.
74. Khaw KT, Woodhouse P. Interrelation of vitamin C, infection, haemostatic factors, and cardiovascular disease. BMJ 1995;310(6994):1559-63.
75. Sullivan DR. Screening for cardiovascular disease with cholesterol. Clin Chim Acta 2002;315(1-2):49-60.
76. Cerna O, Ginter E. Blood lipids and vitamin-C status. Lancet 1978; 1(8072):1055–6.
77. Greco AM, LaRocca L. Correlation between chronic hypovitaminosis C in old age and plasma levels of cholesterol and triglycerides. Int J Vit Nutr Res 1982;23:129-36.
78. Itoh R, Yamada K, Oka J, Echizen H, Suyama Y, Murakami K. Serum ascorbic acid and HDL cholesterol in a healthy elderly Japanese population. Int J Vitam Nutr Res 1990;60(4):360-5.
79. Simon JA, Hudes ES. Relation of serum ascorbic acid to serum lipids and lipoproteins in US adults. J Am Coll Nutr 1998;17(3):250-5.
80. Jacques PF, Sulsky SI, Perrone GE, Jenner J, Schaefer EJ. Effect of vitamin C supplementation on lipoprotein cholesterol, apolipoprotein, and triglyceride concentrations. Ann Epidemiol 1995;5(1):52-9.
81. Harwood HJ Jr, Greene YJ, Stacpoole PW. Inhibition of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by ascorbic acid. An effect mediated by the free radical monodehydroascorbate. J Biol Chem 1986;261(16): 7127-35.
82. Greene YJ, Harwood HJ Jr, Stacpoole PW. Ascorbic acid regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol synthesis in guinea pig liver. Bioch Biophys Acta 1985; 834(1):134-8.
83. Santillo M, Santangelo F, Belfiore A, Mastursi M, Mondola P. Effect of ascorbic acid administration on B and E apoproteins in rats fed a cholesterol enriched diet. Horm Metab Res 1993;25(3):156-9.
84. Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994; 139(12): 1180-9.
85. Stringer MD, Gorog PG, Freeman A, Kakkar VV. Lipid peroxides and atherosclerosis. BMJ 1989;298:281-4.
86. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997;337:408-16.
87. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A 1989;86(16):6377-81.
88. Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 1999;446(2-3):305-8.
89. Lehr HA, Frei B, Olofsson AM, Carew TE, Arfors KE. Protection from oxidized LDL-induced leukocyte adhesion to microvascular and macrovascular endothelium in vivo by vitamin C but not by vitamin E. Circulation 1995;91(5):1525-32.
90. Mak S, Egri Z, Tanna G, Colman R, Newton GE. Vitamin C prevents hyperoxia-mediated vasoconstriction and impairment of endothelium-dependent vasodilation. Am J Physiol Heart Circ Physiol 2002;282(6):H2414-21.
91. Bayerle-Eder M, Pleiner J, Mittermayer F, Schaller G, Roden M, Waldhausl W, et al. Effect of systemic vitamin C on free fatty acid-induced lipid peroxidation. Diabetes Metab 2004;30(5):433-9.
92. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991;88:10045-8.
93. Moran JP, Cohen L, Greene JM, Xu G, Feldman EB, Hames CG, et al. Plasma ascorbic acid concentrations relate inversely to blood pressure in human subjects. Am J Clin Nutr 1993;57:213-7.
94. Bates CJ, Walmsley CM, Prentice A, Finch S. Does vitamin C reduce blood pressure? Results of a large study of people aged 65 or older. J Hyperten 1998;16(7):925-32.
95. Duffy SJ, Gokce N, Holbrook M, Huang A, Frei B, Keaney JF Jr, et al. Treatment of hypertension with ascorbic acid. Lancet 1999;354(9195):2048-9.
96. Chen J, He J, Hamm L, Batuman V, Whelton PK. Serum antioxidant vitamins and blood pressure in the United States population. Hypertension 2002;40(6):810-6.
97. Kritchevsky SB, Shimakawa T, Tell GS, Dennis B, Carpenter M, Eckfeldt JH, et al. Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis risk in communities study. Circulation 1995;92:2142 –50.
98. Joshipura KJ, Hu FB, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med 2001;134:1106-14.
99. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004;61(1):82-8.
100. Montilla-Lopez P, Munoz-Agueda MC, Feijoo Lopez M, Munoz-Castaneda JR, Bujalance-Arenas I, et al. Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer’s disease induced by okadaic acid in neuroblastoma cells. Eur J Pharmacol 2002;451(3):237-43.
101. Parle M, Dhingra D. Ascorbic acid: a promising memory-enhancer in mice. J Pharmacol Sci 2003;93(2):129-35.
102. Chan SW, Reade PC. The role of ascorbicacid in oral cancer and carcinogenesis. Oral Dis 1998;4(2):120-9.
103. Lupulescu A. The role of vitamins A, beta-carotene, E and C in cancer cell biology. Int J Vitam Nutr Res 1994;64(1):3-14.
104. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res 1982;23:103-13.
105. Moertel CG, Fleming TR, Creagan ET, Rubin J, O’connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985;312(3):137-44.
106. Halliwell B. Vitamin C and genomic stability. Mutat Res 2001;475(1-2):29-35.
107. Moorman PG, Ricciuti MF, Millikan RC, Newman B. Vitamin supplement use and breast cancer in a North Carolina population. Public Health Nutr 2001;4(3):821-7.
108. Block G. Epidemiologic evidence regarding vitamin C and cancer. Am J Clin Nutr 1991;54(6):S1310-4.
109. Dusinska M, Kazimirova A, Barancokova M, Beno M, Smolkova B, Horska A, et al. Nutritional supplementation with antioxidants decreases chromosomal damage in humans. Mutagenesis 2003;18(4):371-6.
110. Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, et al. Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res 1998;18:2487-93.
111. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004;140(7):533-7.
112. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR Jr, Wang Y, Levine M. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 1997;14:1133-9.
113. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006;174(7):937-42.
114. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 2005;102(38):13604-9.
115. Byers T, Guerrero N. Epidemiologic evidence for vitamin C and vitamin E in cancer prevention. Am J Clin Nutr 1995;62:1385S -92S.
116. Jenab M, Riboli E, Ferrari P, Sabate J, Slimani N, Norat T, et al. Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Carcinogenesis 2006 Jun 14; Epub ahead of print.
117. Sakagami H, Satoh K, Hakeda Y, Kumegawa M. Apoptosis-inducing activity of vitamin C and vitamin K. Cell Mol Biol 2000;46:129-143.
118. Kang JS, Cho D, Kim YI, Hahm E, Yang Y, Kim D, et al. L-ascorbic acid (vitamin C) induces the apoptosis of B16 murine melanoma cells via a caspase-8-independent pathway. Cancer Immunol Immunother 2003;52(11):693-698.
119. Thomas CG, Vezyraki PE, Kalfakakou VP, Evangelou AM. Vitamin C transiently arrests cancer cell cycle progression in S phase and G(2)/M boundary by modulating the kinetics of activation and the subcellular localization of Cdc25C phosphatase. J Cell Physiol 2005;205(2):310-8.
120. Naidu KA, Tang JL, Naidu KA, Prockop LD, Nicosia SV, Coppola D. Antiproliferative and apoptotic effect of ascorbyl stearate in human glioblastoma multiforme cell: Modulation of insulin-like growth factor-I receptor (IGF-IR) expression. J Neurooncol 2001;54(1):15-22.
121. Naidu AK, Karl RC, Naidu KA, Coppola D. The antiproliferative and pro-apoptotic effect of Ascorbyl Stearate in Human pancreatic cancer cells: Association with decreased expression of insulin-like growth factor receptor-1. Digest Dis Sci 2003;48(1):230-7.
122. Naidu AK. Vitamin C in human health and disease is still a mystery? An overview. Nutr J 2003;2(1):7.
123. Bonnefont-Rousselot D. The role of antioxidant micronutrients in the prevention of diabetic complications. Treat Endocrinol 2004;3(1):41-52.
124. Chen L, Jia RH, Qiu CJ, Ding G. Hyperglycemia inhibits the uptake of dehydroascorbate in tubular epithelial cell. Am J Nephrol 2005;25(5):459-65.
125. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998;31(3):552-7.
126. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97(1):22-8.
127. Chen H, Karne RJ, Hall G, Campia U, Panza JA, Cannon RO 3rd, Wang Y, Katz A, Levine M, Quon MJ. High dose oral vitamin C partially replenishes vitamin C levels in patients with type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol 2006;290(1):H137-45.
128. Choi SW, Benzie IF, Lam CS, Chat SW, Lam J, Yiu CH, et al. Inter-relationships between DNA damage, ascorbic acid and glycaemic control in Type 2 diabetes mellitus. Diabet Med 2005;22(10):1347-53.
129. Simon JA, Hudes ES. Serum ascorbic acid and other correlates of self-reported cataract among older Americans. J Clin Epidemiol 1999;52(12):1207-11.
130. Van der Pols JC. A possible role for vitamin C in age-related cataract. Proc Nutr Soc 1999;58(2):295-301.
131. Cheng R, Lin B, Lee KW, Ortwerth BJ. Similarity of the yellow chromophores isolated from human cataracts with those from ascorbic acid-modified calf lens proteins: evidence for ascorbic acid glycation during cataract formation. Biochim Biophys Acta 2001;1537(1):14-26.
132. Argirov OK, Lin B, Ortwerth BJ. 2-ammonio-6-(3-oxidopyridinium-1-yl)hexanoate (OP-lysine) is a newly identified advanced glycation end product in cataractous and aged human lenses. J Biol Chem 2004;279(8):6487-95.
133. Jacques PF. The potential preventive effects of vitamins for cataract and age-related macular degeneration. Int J Vitam Nutr Res 1999;69(3):198-205.
134. Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 2005;81(4):736-45.
135. Rees DC, Kelsey H, Richards JD. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 1993;306:841-2.
136. Hallberg L. Iron and vitamins. Bibl Nutr Dieta 1995;52:20-9.
137. Cook JD, Watson SS, Simpson KM, Lipschitz DA, Skikne BS. The effect of high ascorbic acid supplementation on body iron stores. Blood 1984;64:721-6.
138. Diplock AT. Antioxidant nutrients and disease prevention: An overview. Am J Clin Nutr 1991;53(1):S189- 93.
139. Meyers DG, Maloley PA, Weeks D. Safety of antioxidant vitamins. Arch Intern Med 1996;156:925-35.
140. Gerster H. No contribution of ascorbic acid to renal calcium oxalate stones. Ann Nutr Metab 1997;41(5):269-82.
141. Wandzilak TR, D’Andre SD, Davis PA, Williams HE. Effect of high dose vitamin C on urinary oxalate levels. J Urol 1994;151(4):834-37.
142. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of the intake of vitamins C, B6, and the risk of kidney stones in men. J Urol 1996;155:1847-51.
143. Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C.Eur J Clin Invest 1998;28(9):695-700.
144. Pena de la Vega L, Lieske JC, Milliner D, Gonyea J, Kelly DG. Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. J Parenter Enteral Nutr 2004;28(6):435-8.
145. Rivers JM. Safety of high-level vitamin C ingestion. Int J Vitam Nutr Res 1989;30:95-102.
146. Stein HB, Hasan A, Fox IH. Ascorbic acid-induced uricosuria. Ann Intern Med 1976;84:385-8.
147. Schmidt KH, Hagmaier V, Hornig DH, Vuilleumier JP, Rutishauser G. Urinary oxalate excretion after large intakes of ascorbic acid in man. Am J Clin Nutr 1981;34(3):305-11.
148. Mitch WE, Johnson MW, Kirshenbaum JM, Lopez RE. Effect of large oral doses of ascorbic acid on uric acid excretion by normal subjects. Clin Pharmacol Ther 1981;29:318-21.
149. Wynne H, Khan T, Avery P, Wood P, Ward A, Kamali F. Dietary related plasma vitamin C concentration has no effect on anticoagulation response to warfarin. Thromb Res 2005 Aug 30; Epub ahead of print.
150. Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D, Hobbs GR. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy 2005;25(2):165-70.
151. Nagayama H, Hamamoto M, Ueda M, Nito C, Yamaguchi H, Katayama Y. The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol 2004;27(6):270-3.